Q3 FY2026
Filed Nov 5, 2026SINTX reports third quarter 2026 total revenue of approximately $2.2 million, more than tenfold the prior-year quarter, with operating loss down 51%
Revenue and gross profit rose sharply and operating expenses fell 13%, but the company still posted a net loss of $(1,595) thousand, nine-month net loss of $(7,122) thousand, cash of $2,005 thousand at September 30, 2026, and cites going-concern risk in its forward-looking statements. Results depend on post-quarter warrant proceeds and further financing.
Key metrics
shortened, hover for the filing’s print| Metric | Value | q/q | y/y |
|---|---|---|---|
| Total revenue, Q3 2026 (three months ended Sep 30, 2026)GAAP | $2,190 thousand (approximately $2.2 million in release text) | – | more than tenfold (release headline) |
| Product revenue, Q3 2026GAAP | $2.09M | – | – |
| Grant and contract revenue, Q3 2026GAAP | $100K | – | – |
| Costs of revenue, Q3 2026GAAP | $828K | – | – |
| Gross profit, Q3 2026GAAP | $1,362 thousand (approximately $1.4 million in release text) | – | – |
| Gross margin, Q3 2026GAAP | approximately 62% | – | – |
| Research and development expense, Q3 2026GAAP | $548K | – | – |
| General and administrative expense, Q3 2026GAAP | $2.25M | – | – |
| Sales and marketing expense, Q3 2026GAAP | $140K | – | – |
| Grant and contract expenses, Q3 2026GAAP | $58K | – | – |
| Total operating expenses, Q3 2026GAAP | $2,997 thousand (approximately $3.0 million in release text) | – | decreased 13% |
| Loss from operations, Q3 2026GAAP | $(1,635) thousand (release text: $1.6 million) | – | decreased 51% |
| Interest income, Q3 2026GAAP | $11K | – | – |
| Total other income (expense), net, Q3 2026GAAP | $40K | – | – |
| Net loss, Q3 2026GAAP | $(1,595) thousand (approximately $1.6 million in release text) | – | decreased 55% |
| Net loss attributable to common stockholders, Q3 2026GAAP | −$1.59M | – | – |
| Net loss per share, basic and diluted, Q3 2026GAAP | $(0.24) | – | – |
| Net loss per share attributable to common stockholders, basic and diluted, Q3 2026GAAP | $(0.24) | – | – |
| Total revenue, nine months ended Sep 30, 2026GAAP | $3,022 thousand (approximately $3.0 million in release text) | – | increased 315% |
| Product revenue, nine months ended Sep 30, 2026GAAP | $2.84M | – | – |
| Grant and contract revenue, nine months ended Sep 30, 2026GAAP | $185K | – | – |
| Costs of revenue, nine months ended Sep 30, 2026GAAP | $1.24M | – | – |
| Gross profit, nine months ended Sep 30, 2026GAAP | $1.78M | – | – |
| Research and development expense, nine months ended Sep 30, 2026GAAP | $1.49M | – | – |
| General and administrative expense, nine months ended Sep 30, 2026GAAP | $7.10M | – | – |
| Sales and marketing expense, nine months ended Sep 30, 2026GAAP | $812K | – | – |
| Total operating expenses, nine months ended Sep 30, 2026GAAP | $9.51M | – | – |
| Loss from operations, nine months ended Sep 30, 2026GAAP | −$7.73M | – | – |
| Change in fair value of derivative liabilities, nine months ended Sep 30, 2026GAAP | $482K | – | – |
| Net loss, nine months ended Sep 30, 2026GAAP | −$7.12M | – | – |
| Net loss attributable to common stockholders, nine months ended Sep 30, 2026GAAP | −$8.05M | – | – |
| Net loss per share, basic and diluted, nine months ended Sep 30, 2026GAAP | $(1.37) | – | – |
| Net loss per share attributable to common stockholders, basic and diluted, nine months ended Sep 30, 2026GAAP | $(1.55) | – | – |
| Cash and cash equivalents, September 30, 2026GAAP | $2,005 thousand (approximately $2.0 million in release text) | – | – |
Segments
| Segment | Revenue | q/q | y/y |
|---|---|---|---|
| Product revenueThe filing does not attribute the change in product revenue to a specific cause. The CEO described the industrial business as providing an important commercial foundation, and the release reports initial commercial sales of the SiNAPTIC Foot & Ankle Osteotomy Wedge System as underway. | $2,090 thousand (Q3 2026); $2,837 thousand (nine months 2026) | – | – |
| Grant and contract revenueThe filing does not explain the grant and contract revenue change. The line was $58 thousand in Q3 2025 and $187 thousand in the nine months ended September 30, 2025. | $100 thousand (Q3 2026); $185 thousand (nine months 2026) | – | – |
Capital returns
- No share repurchases or dividends are reported in the documents.
- Subsequent to quarter end, the company received aggregate gross proceeds of approximately $2.0 million from the exercise of 941,423 Class B warrants at $2.14 per share. The release says this followed a call triggered by achieving the third-quarter revenue milestone of $2 million.
- Deemed dividend from warrant modification of $926 thousand was recorded in the nine months ended September 30, 2026. The statements print no deemed dividend for the Q3 2026 three-month period, and print a $6,719 thousand deemed dividend from warrant inducement in the Q3 2025 and nine months 2025 columns.
What drove it
- The company attributes the gross margin improvement, from 45% to approximately 62%, to improved pricing, higher manufacturing volumes, and increased production efficiencies.
- The release attributes the decline in operating expenses to the reported reductions in the research and development line, which fell from $1,264 thousand to $548 thousand. General and administrative expense rose from $2,102 thousand to $2,251 thousand over the same quarters.
- Limited-use release of the FDA-cleared SiNAPTIC Foot & Ankle Osteotomy Wedge System was completed in Q3 2026 after initiation in Q1 2026.
- A silicon nitride masterclass was sponsored with orthopedic experts to educate surgeons and develop sales channels, according to the release.
Concerns
- Net loss of $(1,595) thousand in Q3 2026 and $(7,122) thousand for the nine months ended September 30, 2026.
- Cash and cash equivalents of $2,005 thousand at September 30, 2026. The release mentions approximately $2.0 million of warrant proceeds received after quarter end, and says the company continues to pursue additional financing alternatives.
- Forward-looking statements list the company's ability to continue as a going concern and to obtain sufficient funding among their risks.
- Forward-looking statements also list customer concentration and the potential loss or reduction of business from significant customers, and the timing and volume of customer orders.
- Total stockholders' equity of $3,390 thousand was close to the $2.5 million Nasdaq requirement that the company says it has regained, so compliance depends on continued results.
- The nine-month deemed dividend of $926 thousand from warrant modification increased the net loss attributable to common stockholders above the net loss.
- Accounts payable rose to $961 thousand and accrued liabilities to $1,190 thousand from $382 thousand and $422 thousand at December 31, 2025.
What to watch
- Whether product revenue sustains above $2,090 thousand in Q4 2026, given the nine-month product revenue of $2,837 thousand.
- Gross margin trajectory from the approximately 62% printed for Q3 2026.
- Cash position after the approximately $2.0 million of Class B warrant proceeds, and any further financing announced.
- Results of large-animal in vivo studies on silicon nitride-treated medical textiles, expected to be completed in the first quarter of 2027 according to the release.
- Commercial uptake of the SiNAPTIC Foot & Ankle Osteotomy Wedge System following initial sales.
- Going-concern language in future filings.
Balance sheet and cash flow
- Cash and cash equivalents were $2,005 thousand at September 30, 2026, compared with $4,140 thousand at December 31, 2025.
- Total assets were $8,903 thousand at September 30, 2026, compared with $9,506 thousand at December 31, 2025.
- Total liabilities were $5,513 thousand at September 30, 2026, compared with $6,577 thousand at December 31, 2025. Total current liabilities were $3,004 thousand.
- Total stockholders' equity was $3,390 thousand at September 30, 2026, compared with $2,929 thousand at December 31, 2025.
- Debt (current) was $55 thousand at September 30, 2026, compared with $7 thousand at December 31, 2025.
- Inventories (current) were $2,555 thousand at September 30, 2026, compared with $825 thousand at December 31, 2025.
- Accounts payable were $961 thousand at September 30, 2026, compared with $382 thousand at December 31, 2025.
- Accumulated deficit was $(299,224) thousand at September 30, 2026, compared with $(292,102) thousand at December 31, 2025.
- The release states the company regained compliance with Nasdaq's minimum stockholders' equity requirement of $2.5 million.
- The release states the company continues to pursue revenue growth, operating efficiencies, and additional financing alternatives to support operations and commercialization activities.
Analysis
SINTX reported third-quarter 2026 total revenue of $2,190 thousand, against $208 thousand in the third quarter of 2025, and the release headline describes this as more than tenfold year-over-year growth. Product revenue was $2,090 thousand against $150 thousand, while grant and contract revenue was $100 thousand against $58 thousand. For the nine months ended September 30, 2026, total revenue was $3,022 thousand, an increase of 315% as printed, with product revenue of $2,837 thousand against $541 thousand in the prior-year period. The release does not give a second-quarter 2026 comparison, so no sequential figures are reported.
Gross profit was $1,362 thousand in the quarter against $93 thousand a year earlier, and gross margin is printed as approximately 62% against 45%. The company attributes this to improved pricing, higher manufacturing volumes, and increased production efficiencies. Costs of revenue were $828 thousand against $115 thousand. Total operating expenses were $2,997 thousand against $3,448 thousand, a decrease of 13%. Within that total, research and development fell to $548 thousand from $1,264 thousand, while general and administrative rose to $2,251 thousand from $2,102 thousand and sales and marketing rose to $140 thousand from $59 thousand. Loss from operations was $(1,635) thousand against $(3,355) thousand, and net loss was $(1,595) thousand against $(3,539) thousand, with basic and diluted loss per share of $(0.24) against $(1.19).
On a nine-month basis the picture is weaker. Operating expenses were $9,514 thousand against $8,676 thousand, driven by general and administrative expense of $7,104 thousand against $4,836 thousand and sales and marketing of $812 thousand against $100 thousand. Net loss was $(7,122) thousand against $(8,149) thousand, and net loss attributable to common stockholders was $(8,048) thousand against $(14,868) thousand, which includes a $926 thousand deemed dividend from warrant modification in 2026 and a $6,719 thousand deemed dividend from warrant inducement in the 2025 period.
The balance sheet shows cash and cash equivalents of $2,005 thousand at September 30, 2026, down from $4,140 thousand at December 31, 2025, and inventories rising to $2,555 thousand from $825 thousand. Total stockholders' equity increased to $3,390 thousand from $2,929 thousand, and the release states the company regained compliance with Nasdaq's $2.5 million minimum stockholders' equity requirement. The company also reports approximately $2.0 million of gross proceeds from the exercise of 941,423 Class B warrants at $2.14 per share after quarter end. Its forward-looking statements list going-concern risk and the need for sufficient funding, and the release states the company continues to pursue additional financing alternatives. No operating or free cash flow figures are printed. No guidance was issued.
Management, verbatim
Our third-quarter results represent a meaningful milestone in the commercial transformation of SINTX Technologies,
Eric Olson, Chief Executive Officer
Our industrial business is providing an important commercial foundation as we pursue what we believe are even greater long-term opportunities in healthcare.
Eric Olson, Chief Executive Officer
With the initial commercial sales of our SiNAPTIC® Foot & Ankle Osteotomy Wedge System underway, we have established a foundation for expanding our presence in the orthopedic implant market.
Eric Olson, Chief Executive Officer
Not in the filing
stated, not guessed- No forward guidance for revenue, gross margin, operating expenses or tax rate is printed in the filing.
- No prior-quarter (Q2 2026) comparison is printed, so sequential changes are null.
- Year-over-year percentage changes for individual revenue lines, cost lines and gross profit are not printed, so those fields are null.
- Cash flow statement is not included: operating cash flow, investing cash flow, financing cash flow and free cash flow are not reported.
- Gross margin change in basis points is not printed.
- Cash and cash equivalents at December 31, 2025 appear only on the balance sheet, not as a same-period comparison row, so no prior-period field is populated for cash.
- Segment-level operating results or segment gross margins are not reported; only the product and grant and contract revenue lines are printed.
- Share price reaction and analyst consensus are not in the documents.
Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.